# Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

> **NCT06652438** · PHASE3 · RECRUITING · sponsor: **Stichting Hemato-Oncologie voor Volwassenen Nederland** · enrollment: 415 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, Adult

## Interventions

- **DRUG:** Revumenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06652438
- **Lead sponsor:** Stichting Hemato-Oncologie voor Volwassenen Nederland
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2029-12-13
- **Final completion:** 2031-07-10
- **Target enrollment:** 415 (ESTIMATED)
- **Last updated:** 2025-04-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06652438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06652438, "Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT06652438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*